Advertisement

Erectile Dysfunction

  • Thorsten Reffelmann
  • Robert A. KlonerEmail author
Chapter
Part of the Contemporary Cardiology book series (CONCARD)

Abstract

Erectile dysfunction is commonly defined as the inability to attain or maintain a penile erection sufficient for satisfactory sexual intercourse. The prevalence, as estimated in a cross-sectional national probability survey in the United States (men aged 40 years and more, May 2001–January 2002), was 22% with significant increase with aging (Laumann, J Sex Med, 4:57–65, 2007). A similar prevalence of 19.2% was found in an urban area in Germany (30–80 years of age), with an increase from 2% among the youngest group to 53% in the oldest group (Braun, Int J Impot Res, 12:305–311, 2000). Twenty-six new cases per 1000 men were the estimated annual incidence of erectile dysfunction determined in the Massachusetts Male Aging Study (40- to 69-year-old men) (Johannes, J Urol, 163:460–463, 2000).

Keywords

Vardenafil Erectile dysfunction Tadalafil Phosphodiesterase-5 inhibitor Sildenafil 

References

  1. 1.
    Laumann EO, West S, Glasser D, Carson C, Rosen R, Kang JH. Prevalence and correlates of erectile dysfunction by race and ethnicity among men aged 40 or older in the United States: from the male attitudes regarding sexual health survey. J Sex Med. 2007;4:57–65.CrossRefGoogle Scholar
  2. 2.
    Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the “Cologne Male Survey”. Int J Impot Res. 2000;12:305–11.CrossRefGoogle Scholar
  3. 3.
    Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40–69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol. 2000;163:460–3.CrossRefGoogle Scholar
  4. 4.
    Levine LA. Diagnosis and treatment of erectile dysfunction. Am J Med. 2000;109:3S–12S.CrossRefGoogle Scholar
  5. 5.
    Benet AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin North Am. 1995;22:699–709.PubMedGoogle Scholar
  6. 6.
    Greiner KA, Weigel JW. Erectile dysfunction. Am Fam Physician. 1996;54:1675–82.PubMedGoogle Scholar
  7. 7.
    Nicolosi A, Moreira E, Shirai M, Bin Mohd Tambi MI, Glasser DB. Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology. 2003;61:201–6.CrossRefGoogle Scholar
  8. 8.
    NIH Consensus Development Panel on Impotence. Impotence. JAMA. 1993;270:83–90.CrossRefGoogle Scholar
  9. 9.
    Nusbaum MR. Erectile dysfunction: prevalence, etiology, and major risk factors. J Am Osteopath Assoc. 2002;102:S1–6.PubMedGoogle Scholar
  10. 10.
    McVary KT, Carrier S, Wessells H, Subcommittee on Smoking and Erectile Dysfunction Socioeconomic Committee, Sexual Medicine Society of North America. Smoking and erectile dysfunction: evidence based analysis. J Urol. 2001;166:1624–32.CrossRefGoogle Scholar
  11. 11.
    Brock GB, Lue TF. Drug-induced male sexual dysfunction. An update. Drug Saf. 1993;8:414–46.CrossRefGoogle Scholar
  12. 12.
    Keene LC, Davies PH. Drug-related erectile dysfunction. Adverse Drug React Toxicol Rev. 1999;18:5–24.PubMedGoogle Scholar
  13. 13.
    Nurnberg HG, Hensley PL, Gelenberg AJ, Fava M, Lauriello J, Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA. 2003;289:56–64.CrossRefGoogle Scholar
  14. 14.
    Roth A, Kalter-Leibovici O, Kerbis Y, et al. Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: a community survey among 1,412 Israeli men. Clin Cardiol. 2003;26:25–30.CrossRefGoogle Scholar
  15. 15.
    Moulik PK, Hardy KJ. Hypertension, anti-hypertensive drug therapy and erectile dysfunction in diabetes. Diabet Med. 2003;20:290–3.CrossRefGoogle Scholar
  16. 16.
    Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet. 1985;1:181–4.CrossRefGoogle Scholar
  17. 17.
    Walczak MK, Lokhandwala N, Hodge MB, Guay AT. Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med. 2002;6:19–24.Google Scholar
  18. 18.
    Kaiser DR, Billups K, Mason C, Wetterling R, Lundberg JL, Bank AJ. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol. 2004;43:179–84.CrossRefGoogle Scholar
  19. 19.
    O’Kane PD, Jackson G. Erectile dysfunction: is there silent obstructive coronary artery disease? Int J Clin Pract. 2001;55:219–20.PubMedGoogle Scholar
  20. 20.
    Gazzaruso C, Giordanetti S, De Amici E, et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation. 2004;110:22–6.CrossRefGoogle Scholar
  21. 21.
    Billups KL. Endothelial dysfunction as a common link between erectile dysfunction and cardiovascular disease. Curr Sex Health Rep. 2004;1:137–41.CrossRefGoogle Scholar
  22. 22.
    Montorsi F, Briganti A, Salonia A, et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol. 2003;44:360–5.CrossRefGoogle Scholar
  23. 23.
    Hodges LD, Kirby M, Solanki J, et al. The temporal relationship between erectile dysfunction and cardiovascular disease. Int J Clin Pract. 2007;61:2019–5.CrossRefGoogle Scholar
  24. 24.
    Montorsi P, Ravagnani PM, Galli S, et al. Association between erectile dysfunction and coronary artery disease: role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J. 2006;27:2632–9.CrossRefGoogle Scholar
  25. 25.
    Peyton CC, Colaco MA, Kovel RC, et al. Erectile dysfunction is predictive of endothelial dysfunction in a well visit population. J Urol. 2016;195:1045–50.CrossRefGoogle Scholar
  26. 26.
    Blumentals WA, Gomez-Caminero A, Joo S, Vannappagari V. Should erectile dysfunction be considered as a marker for acute myocardial infarction? Results from a retrospective cohort study. Int J Impot Res. 2004;16:350–3.CrossRefGoogle Scholar
  27. 27.
    Kloner RA, Mullin SH, Shook T, et al. Erectile dysfunction in the cardiac patient: how common and should we treat? J Urol. 2003;170:S46–50.CrossRefGoogle Scholar
  28. 28.
    Dorey G. Is smoking a cause of erectile dysfunction? A literature review. Br J Nurs. 2001;10:455–65.CrossRefGoogle Scholar
  29. 29.
    Jeremy JY, Mikhailidis DP. Cigarette smoking and erectile dysfunction. J R Soc Health. 1998;118:151–5.CrossRefGoogle Scholar
  30. 30.
    Mirone V, Imhimbo C, Bortolotti A, et al. Cigarette smoking as risk factor for erectile dysfunction: results from an Italian epidemiological study. Eur Urol. 2002;41:294–7.CrossRefGoogle Scholar
  31. 31.
    Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology. 2000;56:302–6.CrossRefGoogle Scholar
  32. 32.
    Romeo JH, Seftel AD, Madhum ZT, Aron DC. Sexual function in men with diabetes type 2: association with glycemic control. J Urol. 2000;163:788–91.CrossRefGoogle Scholar
  33. 33.
    Wassmann S, Laufs U, Bäumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 2001;37:1450–7.CrossRefGoogle Scholar
  34. 34.
    Herrmann HC, Levine LA, Macaluso J, et al. Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. J Sex Med. 2006;3:303–8.CrossRefGoogle Scholar
  35. 35.
    Carvajal A, Macias D, Sáinz M, et al. HMG CoA reductase inhibitors and impotence: two case series from the Spanish and French drug monitoring systems. Drug Saf. 2006;29:143–9.CrossRefGoogle Scholar
  36. 36.
    Solomon H, Samarasinghe YP, Feher MD, et al. Erectile dysfunction and statin treatment in high cardiovascular risk patients. J Clin Pract. 2006;60:141–5.CrossRefGoogle Scholar
  37. 37.
    Ralph D, McNicholas T. Erectile dysfunction alliance. UK management guidelines for erectile dysfunction. BMJ. 2000;321:499–503.CrossRefGoogle Scholar
  38. 38.
    Rizvi K, Hampson JP, Harvey JN. Do lipid-lowering drugs cause erectile dysfunction? A system review. Fam Pract. 2002;19:95–8.CrossRefGoogle Scholar
  39. 39.
    Schachter M. Erectile dysfunction and lipid disorders. Curr Med Res Opin. 2000;16:S9–S12.CrossRefGoogle Scholar
  40. 40.
    Carvajal A, Lérida MT, Sánchez A, Martín LH, de Diego IM. ACE inhibitors and impotence: a case series from the Spanish drug monitoring system. Drug Saf. 1995;13:130–1.CrossRefGoogle Scholar
  41. 41.
    Llisterri JL, Lozano Vidal JV, Aznar Vicente J, et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci. 2001;321:336–41.CrossRefGoogle Scholar
  42. 42.
    Reffelmann T, Kloner RA. Sexual function in hypertensive patients receiving treatment. Vasc Health Risk Manag. 2006;2:447–55.CrossRefGoogle Scholar
  43. 43.
    Hackett G, Krychman M, Baldwin D, et al. Coronary heart disease, diabetes, and sexuality in men. J Sex Med. 2016;13:887–904.CrossRefGoogle Scholar
  44. 44.
    Gianetta E, Feola T, Gianfrilli D, et al. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. BMC Med. 2014;12:185.CrossRefGoogle Scholar
  45. 45.
    Bohlen JG, Held JP, Sanderson MO, Patterson RP. Heart rate, rate–pressure product and oxygen uptake during four sexual activities. Arch Intern Med. 1984;144:1745–8.CrossRefGoogle Scholar
  46. 46.
    Larson JL, McNaughton MW, Kennedy JW, Mansfield LW. Heart rate and blood pressure response to sexual activity and a stair-climbing test. Heart Lung. 1980;9:1025–30.PubMedGoogle Scholar
  47. 47.
    DeBusk R, Drory Y, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol. 2000;86:175–81.CrossRefGoogle Scholar
  48. 48.
    Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the second Princeton consensus conference). Am J Cardiol. 2005;96:313–21.CrossRefGoogle Scholar
  49. 49.
    Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87:766–78.CrossRefGoogle Scholar
  50. 50.
    Levine GN, Steinke EE, Bakaeen FG, et al. Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2012;125:1058–72.CrossRefGoogle Scholar
  51. 51.
    Hatzimouratidis K, Salonia A, Adaikan G, et al. Pharmacotherapy for erectile dysfunction: recommendations from the fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016;13:465–88.CrossRefGoogle Scholar
  52. 52.
    Giuliano F, Jackson G, Montorsi F, et al. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract. 2010;64:240–55.CrossRefGoogle Scholar
  53. 53.
    Mittleman MA, Glasser DB, Orazem J. Clinical trials of sildenafil citrate demonstrate no increase in risk of myocardial infarction and cardiovascular death compared to placebo. Int J Clin Pract. 2003;57:597–600.PubMedGoogle Scholar
  54. 54.
    Hazell L, Boshier A, Harris S, et al. An observational cohort study investigating the cardiovascular safety of tadalafil when prescribed in primary care in England: mortality due to ischemic heart disease. BJU Int. 2007;99:387–93.CrossRefGoogle Scholar
  55. 55.
    Kloner RA, Henderson L. Sexual function in patients with chronic angina pectoris. Am J Cardiol. 2013;11:1671–6.CrossRefGoogle Scholar
  56. 56.
    Swearingen D, Nehra A, Morelos S, et al. Hemodynamic effect of avanafil and glyceryl trinitrate coadministration. Drugs Context. 2013;2013:212248.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Reffelmann T, Kloner RA. Cardiovascular effects of phosphodiesterase 5 inhibitors. Curr Pharm Des. 2006;12:3485–94.CrossRefGoogle Scholar
  58. 58.
    Reffelmann T, Kloner RA. Vardenafil: a selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunction. Expert Opin Pharmacother. 2007;8:965–74.CrossRefGoogle Scholar
  59. 59.
    Reffelmann T, Kloner RA. The cardiovascular safety of tadalafil. Expert Opin Drug Saf. 2008;7:43–52.CrossRefGoogle Scholar
  60. 60.
    Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol. 1999;83:35C–44C.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Medizinische Klinik II, Klinikum Idar-ObersteinIdar-ObersteinGermany
  2. 2.Huntington Medical Research InstitutesPasadenaUSA

Personalised recommendations